Literature DB >> 33668128

Pyrazole Scaffold Synthesis, Functionalization, and Applications in Alzheimer's Disease and Parkinson's Disease Treatment (2011-2020).

Xuefei Li1, Yanbo Yu1, Zhude Tu1.   

Abstract

The remarkable prevalence of pyrazole scaffolds in a versatile array of bioactive molecules ranging from apixaban, an anticoagulant used to treat and prevent blood clots and stroke, to bixafen, a pyrazole-carboxamide fungicide used to control diseases of rapeseed and cereal plants, has encouraged both medicinal and organic chemists to explore new methods in developing pyrazole-containing compounds for different applications. Although numerous synthetic strategies have been developed in the last 10 years, there has not been a comprehensive overview of synthesis and the implication of recent advances for treating neurodegenerative disease. This review first presents the advances in pyrazole scaffold synthesis and their functionalization that have been published during the last decade (2011-2020). We then narrow the focus to the application of these strategies in the development of therapeutics for neurodegenerative diseases, particularly for Alzheimer's disease (AD) and Parkinson's disease (PD).

Entities:  

Keywords:  Alzheimer’s disease; Parkinson’s disease; antagonist; biological activity; functionalization; heterocyclic; inhibitor; neurodegeneration; pyrazole; synthesis

Mesh:

Substances:

Year:  2021        PMID: 33668128      PMCID: PMC7956461          DOI: 10.3390/molecules26051202

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  135 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  PE859, A Novel Curcumin Derivative, Inhibits Amyloid-β and Tau Aggregation, and Ameliorates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8.

Authors:  Michiaki Okuda; Yuki Fujita; Ichiro Hijikuro; Mei Wada; Takuya Uemura; Yukako Kobayashi; Tomonori Waku; Naoki Tanaka; Takaaki Nishimoto; Yasuhiko Izumi; Toshiaki Kume; Akinori Akaike; Takashi Takahashi; Hachiro Sugimoto
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Silver-mediated cycloaddition of alkynes with CF3CHN2: highly regioselective synthesis of 3-trifluoromethylpyrazoles.

Authors:  Feng Li; Jing Nie; Long Sun; Yan Zheng; Jun-An Ma
Journal:  Angew Chem Int Ed Engl       Date:  2013-04-24       Impact factor: 15.336

4.  Acute Rodent Tolerability, Toxicity, and Radiation Dosimetry Estimates of the S1P1-Specific Radioligand [11C]CS1P1.

Authors:  Hui Liu; Richard Laforest; Jiwei Gu; Zonghua Luo; Lynne A Jones; Robert J Gropler; Tammie L S Benzinger; Zhude Tu
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

5.  Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.

Authors:  F Sherif; C G Gottfries; I Alafuzoff; L Oreland
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

6.  Synthesis of pyrazoles from 1,3-diols via hydrogen transfer catalysis.

Authors:  Daniel C Schmitt; Alexandria P Taylor; Andrew C Flick; Robert E Kyne
Journal:  Org Lett       Date:  2015-02-26       Impact factor: 6.005

7.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

Authors:  M Sano; C Ernesto; R G Thomas; M R Klauber; K Schafer; M Grundman; P Woodbury; J Growdon; C W Cotman; E Pfeiffer; L S Schneider; L J Thal
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

8.  Radical Addition of Hydrazones by α-Bromo Ketones To Prepare 1,3,5-Trisubstituted Pyrazoles via Visible Light Catalysis.

Authors:  Xiu-Wei Fan; Tao Lei; Chao Zhou; Qing-Yuan Meng; Bin Chen; Chen-Ho Tung; Li-Zhu Wu
Journal:  J Org Chem       Date:  2016-07-14       Impact factor: 4.354

9.  Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.

Authors:  Jens Wagner; Sergey Ryazanov; Andrei Leonov; Johannes Levin; Song Shi; Felix Schmidt; Catharina Prix; Francisco Pan-Montojo; Uwe Bertsch; Gerda Mitteregger-Kretzschmar; Markus Geissen; Martin Eiden; Fabienne Leidel; Thomas Hirschberger; Andreas A Deeg; Julian J Krauth; Wolfgang Zinth; Paul Tavan; Jens Pilger; Markus Zweckstetter; Tobias Frank; Mathias Bähr; Jochen H Weishaupt; Manfred Uhr; Henning Urlaub; Ulrike Teichmann; Matthias Samwer; Kai Bötzel; Martin Groschup; Hans Kretzschmar; Christian Griesinger; Armin Giese
Journal:  Acta Neuropathol       Date:  2013-04-19       Impact factor: 17.088

10.  Synthesis of 3-trifluoromethylpyrazoles via trifluoromethylation/cyclization of α,β-alkynic hydrazones using a hypervalent iodine reagent.

Authors:  Guojing Ji; Xi Wang; Songnan Zhang; Yan Xu; Yuxuan Ye; Ming Li; Yan Zhang; Jianbo Wang
Journal:  Chem Commun (Camb)       Date:  2014-04-28       Impact factor: 6.222

View more
  2 in total

1.  Carbonic Anhydrase Inhibition with Sulfonamides Incorporating Pyrazole- and Pyridazinecarboxamide Moieties Provides Examples of Isoform-Selective Inhibitors.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Mariana Pinteala; Volodymyr Brovarets; Roman Vydzhak; Svitlana Panchishin; Athina Geronikaki; Claudiu T Supuran
Journal:  Molecules       Date:  2021-11-20       Impact factor: 4.411

2.  Pyrazolo[4,3-c]pyridine Sulfonamides as Carbonic Anhydrase Inhibitors: Synthesis, Biological and In Silico Studies.

Authors:  Andrea Angeli; Victor Kartsev; Anthi Petrou; Boris Lichitsky; Andrey Komogortsev; Mariana Pinteala; Athina Geronikaki; Claudiu T Supuran
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.